J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia
TL;DR: Gene fusions in hematopoietic malignancies are often primary drivers that define many aspects of these diseases.
Journal ArticleDOI
Correction to Targeting the c-Kit Promoter G-quadruplexes with 6-Substituted Indenoisoquinolines
Mallesham Bejugam,Mekala Gunaratnam,Sebastian Müller,Deborah A. Sanders,Sven Sewitz,Jonathan A. Fletcher,Stephen Neidle,Shankar Balasubramanian +7 more
TL;DR: The authors would like to acknowledge, via this correction, that synthetic routes to 6-substituted indenoisoquinolines and other related indenISQs have been previously published and that these citations were an oversight.
Journal ArticleDOI
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
Elisa Fiorito,Patrycja Szybowska,Ellen Margrethe Haugsten,Michal Kostas,Geir Frode Øy,Antoni G Wiedlocha,Sachin Kumar Singh,Sigve Nakken,Gunhild Mari Mælandsmo,Jonathan A. Fletcher,Leonardo A. Meza-Zepeda,Jørgen Wesche +11 more
TL;DR: In this paper , the authors evaluated biologic properties and targeting strategies for the FGFR4 V550L activating mutation in RMS559 cells, which have a high allelic fraction of this mutation and are oncogenically dependent on FGFR 4 signalling.
Journal ArticleDOI
Molecular alterations in sarcomas
TL;DR: Within the last decade, advances in tumor cytogenetics and molecular biology have led to an explosion of information related to the underlying molecular alterations in sarcomas, revealing characteristic genetic findings that shed light on mechanisms of tumorigenesis.
Involvement in Varied Mesenchymal Cell Types and Evidence for Alternative Oncogenic Mechanisms
David Gisselsson,Michele K. Hibbard,Paola Dal Cin,Raf Sciot,Bae-Li Hsi,Harry P.W. Kozakewich,Jonathan A. Fletcher +6 more
TL;DR: These studies provide biological validation for the clinical observation that lipoblastomas can evolve into mature, lipoma-like, lesions and suggest that PLAG1 dosage alterations caused by polysomy 8 might represent an alternative oncogenic mechanism inlipoblastoma.